LCM
SPRB

Laurion Capital Management’s Spruce Biosciences SPRB Stock Holding History

Laurion Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-151
Closed -$51K – 752
2021
Q4 		$51K Hold
151
– – ﹤0.01% 519
2021
Q3 		$68K Sell
151
-48
-24% -$30.1K ﹤0.01% 654
2021
Q2 		$168K Sell
199
-68
-25% -$72.6K ﹤0.01% 654
2021
Q1 		$332K Hold
267
– – ﹤0.01% 638
2020
Q4 		$486K Buy
+267
New +$443K ﹤0.01% 488

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Laurion Capital Management's SPRB Position: Q1 2022 in Review

Laurion Capital Management sold out of Spruce Biosciences (SPRB) in Q1 2022, closing a stake of 151 shares — an estimated $51K sold.

Laurion Capital Management first reported a position in SPRB in Q4 2020 and held it in 5 quarters. The position peaked at $486K in Q4 2020. 43 funds tracked by Wall St. Rank hold SPRB as of Q1 2022.

  • Laurion Capital Management reported no remaining Spruce Biosciences position as of Q1 2022 after selling out during the quarter.
  • Laurion Capital Management sold 151 Spruce Biosciences shares in Q1 2022, an estimated $51K.
  • Laurion Capital Management first reported a position in Spruce Biosciences in Q4 2020 and held it in 5 quarters.
  • Laurion Capital Management's Spruce Biosciences position peaked at $486K in Q4 2020.
  • 43 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2022.

Based on Laurion Capital Management's 13F filing for Q1 2022, filed 16 May 2022.